Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Research Article

Solanum nigrum Anticancer Effect Through Epigenetic Modulations in Breast Cancer Cell Lines

Author(s): Atefeh Shirkavand, Zahra N. Boroujeni and Seyed A. Aleyasin*

Volume 16, Issue 2, 2020

Page: [121 - 126] Pages: 6

DOI: 10.2174/1573394715666190101114541

Price: $65

Abstract

Background: DNA methylation plays an important role in the regulation of gene expression in mammalian cells and often occurs at CpG islands in the genome. It is more reversible than genetic variations and has therefore attracted much attention for the treatment of many diseases, especially cancer. In the present study, we investigated the effect of Solanum nigrum Extract (SNE) on the methylation status of the VIM and CXCR4 genes in breast cancer cell lines.

Methods: The Trypan blue assay was used to study the effect of SNE at various concentrations of 0, 0.1, 1.5, 2.5, 3.5 and 5 mg/ml for 48 h on the survival of three human breast cancer cell lines MCF7, MDA-MB-468, MDA-MB-231. Methylation status of VIM and CXCR4 genes in breast cancer cell lines was assessed by Methylation-Specific PCR (MSP) method. Also, methylation changes of VIM and CXCR4 genes in breast cancer cell lines after treatment with 0.1 mg/ml of SNE for 6 days were analyzed by MSP method. To confirm the effect of SNE on methylation of VIM and CXCR4 genes, Real-Time PCR was performed.

Results: The Trypan blue assay results indicated that treatment with SNE reduced cell viability in a dose-dependent manner in breast cancer cells. Our results showed that treatment of breast cancer cells with 0.1 mg/ml of SNE hypermethylated the VIM, CXCR4 genes and significantly reduced the expression levels of their mRNA (P<0.05).

Conclusion: Our findings reveal for the first time the impact of SNE on the methylation of breast cancer cells.

Keywords: Solanum nigrum, methylation, breast cancer, SNE, carcinogenesis, epigenetic.

Graphical Abstract

[1]
Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 2008; 9(6): 394-408.
[http://dx.doi.org/10.2174/138920208785699580] [PMID: 19506729]
[2]
Slatkin M. Epigenetic inheritance and the missing heritability problem. Genetics 2009; 182(3): 845-50.
[http://dx.doi.org/10.1534/genetics.109.102798] [PMID: 19416939]
[3]
Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002; 21(35): 5380-7.
[http://dx.doi.org/10.1038/sj.onc.1205598] [PMID: 12154400]
[4]
Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28(10): 1069-78.
[http://dx.doi.org/10.1038/nbt.1678] [PMID: 20944599]
[5]
Rønneberg JA, Fleischer T, Solvang HK, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011; 5(1): 61-76.
[http://dx.doi.org/10.1016/j.molonc.2010.11.004] [PMID: 21212030]
[6]
Fleischer T, Edvardsen H, Solvang HK, et al. Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients. Int J Cancer 2014; 134(11): 2615-25.
[http://dx.doi.org/10.1002/ijc.28606] [PMID: 24395279]
[7]
Fleischer T, Frigessi A, Johnson KC, et al. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol 2014; 15(8): 435-43.
[PMID: 25146004]
[8]
Fackler MJ, Umbricht CB, Williams D, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011; 71(19): 6195-207.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1630] [PMID: 21825015]
[9]
Jovanovic J, Rønneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol 2010; 4(3): 242-54.
[http://dx.doi.org/10.1016/j.molonc.2010.04.002] [PMID: 20627830]
[10]
Kato K, Long NK, Makita H, et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer 2008; 99(4): 647-54.
[http://dx.doi.org/10.1038/sj.bjc.6604521] [PMID: 18665171]
[11]
Jain R, Sharma A, Gupta S, Sarethy IP, Gabrani R. Solanum nigrum: current perspectives on therapeutic properties. Altern Med Rev 2011; 16(1): 78-85.
[PMID: 21438649]
[12]
Perez RM, Perez JA, Garcia LM, Sossa H. Neuropharmacological activity of Solanum nigrum fruit. J Ethnopharmacol 1998; 62(1): 43-8.
[http://dx.doi.org/10.1016/S0378-8741(98)00059-2] [PMID: 9720610]
[13]
Son YO, Kim J, Lim JC, Chung Y, Chung GH, Lee JC. Ripe fruit of Solanum nigrum L. inhibits cell growth and induces apoptosis in MCF-7 cells. Food Chem Toxicol 2003; 41(10): 1421-8.
[http://dx.doi.org/10.1016/S0278-6915(03)00161-3] [PMID: 12909277]
[14]
Sultana S, Perwaiz S, Iqbal M, Athar M. Crude extracts of hepatoprotective plants, Solanum nigrum and Cichorium intybus inhibit free radical-mediated DNA damage. J Ethnopharmacol 1995; 45(3): 189-92.
[http://dx.doi.org/10.1016/0378-8741(94)01214-K] [PMID: 7623482]
[15]
Lin HM, Tseng HC, Wang CJ, et al. Induction of autophagy and apoptosis by the extract of Solanum nigrum Linn in HepG2 cells. J Agric Food Chem 2007; 55(9): 3620-8.
[http://dx.doi.org/10.1021/jf062406m] [PMID: 17419635]
[16]
Katz E, Dubois-Marshall S, Sims AH, et al. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS One 2011; 6(2): e17083
[http://dx.doi.org/10.1371/journal.pone.0017083] [PMID: 21347235]
[17]
Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003; 5: 59-63.
[http://dx.doi.org/10.1038/ncb898]
[18]
Challa AA, Stefanovic B. A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol Cell Biol 2011; 31(18): 3773-89.
[http://dx.doi.org/10.1128/MCB.05263-11] [PMID: 21746880]
[19]
Ivaska J. Vimentin: Central hub in EMT induction? Small GTPases 2011; 2(1): 51-3.
[http://dx.doi.org/10.4161/sgtp.2.1.15114] [PMID: 21686283]
[20]
Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97(15): 1124-32.
[http://dx.doi.org/10.1093/jnci/dji204] [PMID: 16077070]
[21]
Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824): 50-6.
[http://dx.doi.org/10.1038/35065016] [PMID: 11242036]
[22]
Lai YJ, Tai CJ, Wang CW, et al. Anti-cancer activity of Solanum nigrum (AESN) through suppression of mitochondrial function and Epithelial-Mesenchymal Transition (EMT) in breast cancer cells. Molecules 2016; 21(5): 553.
[http://dx.doi.org/10.3390/molecules21050553] [PMID: 27136519]
[23]
Jeong JB, Jeong HJ, Park JH, et al. Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein (Rb). J Agric Food Chem 2007; 55(26): 10707-13.
[http://dx.doi.org/10.1021/jf072363p] [PMID: 18038993]
[24]
Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 2009; 50(4): 455-63.
[http://dx.doi.org/10.3349/ymj.2009.50.4.455] [PMID: 19718392]
[25]
Ateeq B, Unterberger A, Szyf M, Rabbani SA. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008; 10(3): 266-78.
[http://dx.doi.org/10.1593/neo.07947] [PMID: 18320071]
[26]
Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One 2010; 5(9): e12710
[http://dx.doi.org/10.1371/journal.pone.0012710] [PMID: 20856924]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy